Invention Grant
US08735438B2 Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
有权
取代的芳基-2-苯基乙基-1H-咪唑化合物作为α2B和/或α2C肾上腺素能受体的亚型选择性调节剂
- Patent Title: Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
- Patent Title (中): 取代的芳基-2-苯基乙基-1H-咪唑化合物作为α2B和/或α2C肾上腺素能受体的亚型选择性调节剂
-
Application No.: US12966560Application Date: 2010-12-13
-
Publication No.: US08735438B2Publication Date: 2014-05-27
- Inventor: Santosh C. Sinha , Todd M. Heidelbaugh , Smita Bhat , Ken Chow , Michael Garst
- Applicant: Santosh C. Sinha , Todd M. Heidelbaugh , Smita Bhat , Ken Chow , Michael Garst
- Applicant Address: US CA Irvine
- Assignee: Allergan, Inc.
- Current Assignee: Allergan, Inc.
- Current Assignee Address: US CA Irvine
- Agent Doina G. Ene
- Main IPC: A61K31/4164
- IPC: A61K31/4164 ; C07D233/54
Abstract:
A compound having selective modulating activity at the alpha 2B and/or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1: wherein n=1-4; X is C or N; R1-R6 can be the same or different and are independently selected from the group consisting of H, C1-6 alkyl, OCH3, OH, F, Cl, Br, CH2OH, CH2N(R7)2, C(O)R8, CH2CN, CF3, wherein R7 is H or C1-6 alkyl; and R8 is C1-6 alkyl or aryl. The compounds of Formula 1 can be incorporated in pharmaceutical compositions and used in methods of treatment of alpha 2 receptor mediated diseases and conditions.
Public/Granted literature
Information query
